Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 3
1997 1
1998 6
1999 7
2000 17
2001 14
2002 21
2003 45
2004 33
2005 36
2006 29
2007 30
2008 23
2009 25
2010 23
2011 25
2012 34
2013 24
2014 26
2015 25
2016 23
2017 16
2018 14
2019 10
2020 13
2021 7
2022 9
2023 5
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

508 results

Results by year

Filters applied: . Clear all
Page 1
Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.
Ochoa D, Román M, Cabaleiro T, Saiz-Rodríguez M, Mejía G, Abad-Santos F. Ochoa D, et al. BMC Pharmacol Toxicol. 2020 Jul 25;21(1):54. doi: 10.1186/s40360-020-00433-2. BMC Pharmacol Toxicol. 2020. PMID: 32711578 Free PMC article. Clinical Trial.
We aimed to evaluate the effect of food on the pharmacokinetics of omeprazole, rabeprazole, and pantoprazole. SETTING: The study population comprised 186 healthy volunteers participating in 6 bioequivalence clinical trials. METHOD: Subjects were evaluated to determine the …
We aimed to evaluate the effect of food on the pharmacokinetics of omeprazole, rabeprazole, and pantoprazole. SETTING: The study popu …
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P Jr, Katz PO, Chen Y, Sostek M. Miner P Jr, et al. Am J Gastroenterol. 2003 Dec;98(12):2616-20. doi: 10.1111/j.1572-0241.2003.08783.x. Am J Gastroenterol. 2003. PMID: 14687806 Clinical Trial.
The objective of this study was to evaluate and compare intragastric pH following standard doses of esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole. METHODS: This randomized, open-label, comparative five-way crossover study evaluated the 24-h intragast …
The objective of this study was to evaluate and compare intragastric pH following standard doses of esomeprazole, lansoprazole, omeprazole, …
Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastric pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A, Aydın D, Kocaman O, Konduk BT, Şentürk Ö, Hülagü S. Çelebi A, et al. Turk J Gastroenterol. 2016 Sep;27(5):408-414. doi: 10.5152/tjg.2016.15514. Turk J Gastroenterol. 2016. PMID: 27782887 Free article. Clinical Trial.
Esomeprazole, rabeprazole, and lansoprazole were found to be superior to pantoprazole on the first day of treatment. ...When the time needed to raise the intragatric pH to over 4 was evaluated, esomeprazole was found to have the most rapid action, followed by lansoprazole …
Esomeprazole, rabeprazole, and lansoprazole were found to be superior to pantoprazole on the first day of treatment. ...When the time …
Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.
Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, Shiramoto M. Sakurai Y, et al. Aliment Pharmacol Ther. 2015 Sep;42(6):719-30. doi: 10.1111/apt.13325. Epub 2015 Jul 21. Aliment Pharmacol Ther. 2015. PMID: 26193978 Free article. Clinical Trial.
METHODS: In this randomised, open-label, two-period cross-over study, vonoprazan 20 mg and esomeprazole 20 mg (Study V vs. E) or rabeprazole 10 mg (Study V vs. R) were orally administered daily for 7 days. ...RESULTS: Acid-inhibitory effect (pH4 HTR) of vonoprazan was sign …
METHODS: In this randomised, open-label, two-period cross-over study, vonoprazan 20 mg and esomeprazole 20 mg (Study V vs. E) or rabepraz
Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Chen S, Shen W, Liu Y, Dong Q, Shi Y. Chen S, et al. Chin Med J (Engl). 2023 Jul 20;136(14):1690-1698. doi: 10.1097/CM9.0000000000002696. Epub 2023 May 22. Chin Med J (Engl). 2023. PMID: 37469024 Free PMC article. Clinical Trial.
Patients with H. pylori infection were randomly (1:1:1) assigned to receive berberine triple therapy (berberine 500 mg, amoxicillin 1000 mg, vonoprazan 20 mg, A group), vonoprazan quadruple therapy (vonoprazan 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, colloidal bismuth t …
Patients with H. pylori infection were randomly (1:1:1) assigned to receive berberine triple therapy (berberine 500 mg, amoxicillin 1000 mg, …
A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection.
Mansour NM, Hashash JG, El-Halabi M, Ghaith O, Maasri K, Sukkarieh I, Malli A, Sharara AI. Mansour NM, et al. Eur J Gastroenterol Hepatol. 2011 Oct;23(10):865-70. doi: 10.1097/MEG.0b013e3283496502. Eur J Gastroenterol Hepatol. 2011. PMID: 21811161 Review.
METHODS: A total of 115 consecutive patients with documented infection were enrolled in this open-label trial. Group A (standard dose) received rabeprazole (20 mg), amoxicillin (1 g), and clarithromycin (500 mg), all twice daily for 10 days. Group B (half dose) received …
METHODS: A total of 115 consecutive patients with documented infection were enrolled in this open-label trial. Group A (standard dose) recei …
Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.
Han YY, Zhou L, Hu YL, Ding XW, Long H, Liu F, Xu M, Zhang ZY, Li SL, Wang QY, Su CX, Chen Y, Chen J, Lin Y, Li PY. Han YY, et al. J Gastroenterol. 2023 Dec;58(12):1167-1177. doi: 10.1007/s00535-023-02042-2. Epub 2023 Oct 1. J Gastroenterol. 2023. PMID: 37777987 Clinical Trial.
This study aimed to compare efficacy and safety of the 10-day vonoprazan-amoxicillin (VA) and 14-day rabeprazole-amoxicillin (RA) dual therapy, and to provide a more efficient, safer, and convenient dual regimen for H. pylori infection. ...The participants were randomly as …
This study aimed to compare efficacy and safety of the 10-day vonoprazan-amoxicillin (VA) and 14-day rabeprazole-amoxicillin (RA) dua …
Metagenomic Changes of Gut Microbiota following Treatment of Helicobacter pylori Infection with a Simplified Low-Dose Quadruple Therapy with Bismuth or Lactobacillus reuteri.
Dore MP, Sau R, Niolu C, Abbondio M, Tanca A, Bibbò S, Loria M, Pes GM, Uzzau S. Dore MP, et al. Nutrients. 2022 Jul 6;14(14):2789. doi: 10.3390/nu14142789. Nutrients. 2022. PMID: 35889746 Free PMC article. Clinical Trial.
METHODS: Forty-six patients infected with H. pylori were prospectively enrolled in a single-centre, randomized controlled trial to receive b.i.d. with meals for 10 days low-dose quadruple therapy consisting of rabeprazole 20 mg and bismuth (two capsules of Pylera() plus 25 …
METHODS: Forty-six patients infected with H. pylori were prospectively enrolled in a single-centre, randomized controlled trial to receive b …
Optimized sequential therapy vs 10- and 14-d concomitant therapy for eradicating Helicobacter pylori: A randomized clinical trial.
Seddik H, Benass J, Berrag S, Sair A, Berraida R, Boutallaka H. Seddik H, et al. World J Gastroenterol. 2024 Feb 14;30(6):556-564. doi: 10.3748/wjg.v30.i6.556. World J Gastroenterol. 2024. PMID: 38463026 Free PMC article. Clinical Trial.
METHODS: This open-label prospective study randomized 328 patients with confirmed H. pylori infection into three groups (1:1:1): The first group received quadruple therapy consisting of twice-daily (bid) omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 5 …
METHODS: This open-label prospective study randomized 328 patients with confirmed H. pylori infection into three groups (1:1:1): The first g …
Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
Xie Y, Zhu Z, Wang J, Zhang L, Zhang Z, Lu H, Zeng Z, Chen S, Liu D, Lv N; the Chinese Study Group on Helicobacter pylori, Chinese Society of Gastroenterology. Xie Y, et al. Antimicrob Agents Chemother. 2018 Aug 27;62(9):e00432-18. doi: 10.1128/AAC.00432-18. Print 2018 Sep. Antimicrob Agents Chemother. 2018. PMID: 29914954 Free PMC article. Clinical Trial.
The objective of this study was to investigate the efficacy and safety of 10-day bismuth quadruple therapy with amoxicillin, tetracycline, or clarithromycin and different doses of rabeprazole for first-line treatment of Helicobacter pylori infection. ...A total of 431 H. p …
The objective of this study was to investigate the efficacy and safety of 10-day bismuth quadruple therapy with amoxicillin, tetracycline, o …
508 results